Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13863MR)

This product GTTS-WQ13863MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13863MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1249MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ4225MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ2355MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ7079MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ1349MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-806
GTTS-WQ14371MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ849MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ5399MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CD58-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW